Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ - A nested case-control study.
CONCLUSIONS: With this unbiased study design and representative group of DCIS patients treated by BCS alone, COX-2, HER2, and periductal fibrosis were revealed as promising markers predicting progression of DCIS into iIBC. Validation will be done in independent data sets. Ultimately, this will aid individual risk stratification of women with primary DCIS.
PMID: 29685879 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Visser LL, Elshof LE, Schaapveld M, Van de Vijver K, Groen EJ, Almekinders MM, Bierman C, Van Leeuwen FE, Rutgers EJT, Schmidt MK, Lips EH, Wesseling J Tags: Clin Cancer Res Source Type: research
More News: Breast Cancer | Breast Carcinoma | Breast Conservation Surgery | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | HER2 | Study | Women